Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Considers Taxotere Name Change To Avoid Misuse In Japan

This article was originally published in PharmAsia News

Executive Summary

Sanofi-Aventis is considering a name change for cancer drug Taxotere (docetaxel) in Japan, according to officials at Japan's Ministry of Health, Labor and Welfare

You may also be interested in...



FTC Notifies ReJuvenation ‘Anti-Aging’ Pill Purchasers To Expect (Or Request) Mailed Refunds

The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.

Executives On The Move: New CEOs At Cyxone And Innoviva, Promotions At Celyad

Exits from Pfizer and Gilead as executives move to Oligomerix Inc. and Pandion Therapeutics, respectively, while chief medical officers are appointed at Exicure and Larimar Therapeutics Inc.

Another Setback For Santhera’s Idebenone DMD Hopes

Santhera needs more time to address concerns regarding its current EU application for idebenone in the DMD setting but the Swiss biotech is keeping its sights on a broader indication.

UsernamePublicRestriction

Register

AG032836

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel